FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia
Incorporating quizartinib into standard treatment for newly diagnosed acute myeloid leukemia (AML) followed by maintenance therapy with the investigational FLT3 inhibitor improved survival for patients with internal-tandem-duplication (ITD) mutations of FLT3, a placebo-controlled randomized trial showed. In the phase III study of over 500 patients undergoing standard induction and consolidation therapy, median overall survival (OS) […]
Clinical Challenges: Treating AML With IDH1 and IDH2 Mutations
About 20% of acute myeloid leukemia (AML) harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. Within the last decade, treatment for these patients “has changed significantly” with the development of first-in-class IDH1 and IDH2 inhibitors, said Tapan Kadia, MD, of the MD Anderson Cancer Center in Houston. Moreover, “treatment paradigms are […]
AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT
NEW ORLEANS — Patients with relapsed or refractory acute myeloid leukemia (AML) achieved similar outcomes with allogeneic hematopoietic stem-cell transplant (allo-HCT) whether they went to transplant as soon as possible or underwent intensive salvage chemotherapy first, the randomized ASAP trial suggested. At day 56 post-transplant, complete remission (CR) rates were a similar 84.1% for patients […]